Surgical Explantation of a Lotus Transcatheter Aortic Valve

Helen Duenas; J Hunter Mehaffey; Leora T Yarboro

doi:10.1016/j.athoracsur.2021.12.015

Surgical Explantation of a Lotus Transcatheter Aortic Valve

Ann Thorac Surg. 2022 Oct;114(4):e273-e274. doi: 10.1016/j.athoracsur.2021.12.015. Epub 2022 Jan 6.

Authors

Helen Duenas¹, J Hunter Mehaffey², Leora T Yarboro¹

Affiliations

¹ Division of Cardiac Surgery, Department of Surgery, University of Virginia Health System, Charlottesville, Virginia.
² Division of Cardiac Surgery, Department of Surgery, University of Virginia Health System, Charlottesville, Virginia. Electronic address: jhm9t@virginia.edu.

PMID: 34998734
DOI: 10.1016/j.athoracsur.2021.12.015

Abstract

The Lotus (Boston Scientific) valve stood out from alternative transcatheter aortic valve replacement (TAVR) valves because of its ability to recapture and redeploy if initial placement was unsatisfactory. With the exponential rise in TAVR, there have been numerous reports of TAVR valve explantation. A 79-year-old man with nonrheumatic aortic valve stenosis who had undergone TAVR with a Lotus valve 12 months earlier presented for surgical excision for early valve failure. The Food and Drug Administration stated that already implanted Lotus valves are not a safety issue; however, cases of valve degeneration will occur, necessitating future valve explantation.

Publication types

Case Reports

MeSH terms

Aged
Aortic Valve / surgery
Aortic Valve Stenosis* / surgery
Heart Valve Prosthesis*
Humans
Male
Prosthesis Design
Risk Factors
Transcatheter Aortic Valve Replacement*
Treatment Outcome